key: cord-0878351-y2f0zdwr
authors: Vossler, David G.
title: COVID-19 Incidence and Death Rate in Epilepsy: Too Early to Tell?
date: 2021-04-30
journal: Epilepsy Curr
DOI: 10.1177/15357597211014195
sha: 3e162b491a2fb6fdc83da90a393afa7c0407c876
doc_id: 878351
cord_uid: y2f0zdwr

nan

A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged in December 2019 resulting in a pandemic. The clinical syndrome, coronavirus disease 2019 (COVID-19), has well-recognized pulmonary manifestations, but an expanding literature reports the acute, subacute, and longer term effects on the central and peripheral nervous systems. Persons having the longer term effects are designated to suffer from post-acute sequelae of COVID-19.

Coronaviruses are large, enveloped, RNA viruses separated into 3 genera: alphacoronaviruses, betacoronaviruses, and gammacoronaviruses. 1 These viruses infect humans and typically cause upper or lower respiratory tract, neurological, gastrointestinal, or hepatic disease. There are currently 7 known coronaviruses that can infect humans: of those, 3 (SARS-CoV-2, SARS-CoV1, and Middle East respiratory syndrome coronavirus) are associated with severe disease. 1 Severe acute respiratory syndrome coronavirus-1 (SARS-CoV1) was detected in the cerebrospinal fluid (CSF) using polymerase chain reaction (PCR), and virions were visualized using electron microscopy in neurons in brain tissue specimens, from autopsy donors infected with severe acute respiratory syndrome during the pandemic of 2002 to 2003. 1 Both SARS-CoV-2 and SARS-CoV1 share a close gene sequence homology and use spike proteins on the viral envelope to bind to mammalian host cells at the angiotensinconverting enzyme 2 receptor. Angiotensin-converting enzyme 2 receptors are found on cells in many organs including the vascular endothelia of the central nervous system. 1 Infection of human brains by SARS-CoV-2 has been suggested in several studies in which viral RNA or protein was detected in the brains and CSF of COVID-19 patients with neurological symptoms. 2, 3 Human-induced pluripotent stem cells have been used to generate brain organoids including neural progenitor cells, neurons, astrocytes, oligodendrocytes, and brain microvascular endothelial cells. Experiments in which such brain organoids were exposed to SARS-CoV-2 showed viral infection, degeneration, and death of neurons and astrocytes. 2, 3 This suggests that SARS-CoV-2 is neurotropic. imaging biomarker for secondary generalization of seizures. However, the study methods and data/result presentation are complicated and require some attention before we dive deeper into the discussion of the results. The authors present data of a large but overall heterogeneous group of TLE patients-MRI-negative patients, patients with hippocampal sclerosis, dysembryoplastic neuroepithelial tumors, and cavernomas. While not necessarily a major problem, combining all these groups prior to showing that their task-related fMRI activations are not different (and that thalamic activations are not different) creates a potential confounder that is not addressed in the study. Further, they utilize their "goto" fMRI task-verb fluency-to assess language lateralization including thalamic involvement in the task. However, since there is no performance tracking with this covert task, there is no way of knowing how well the participants performed the task and how performance on the task influenced the observed fMRI activations. To offset this, they tested letter fluency as part of their neuropsychological battery-there were some group differences including significant differences between left TLE with and without generalized seizures.

In the primary analysis, they compared fMRI activation patterns in patients with FBTCS within the last year to patients with no FBTCS (ie, only with focal seizures [FS] ) in the last year to find that the activation patterns were different between the groups with higher fMRI activation and more leftward activation in patients with FS including differences in thalami. Of interest is the fact that some of the peak activations fell into the anterior thalamic nuclei that, as we all know, are the target of deep brain stimulation. In the post hoc analyses, they showed that FS patients' thalamic activations were similar to healthy controls performing the same task but active FBTCS participants had overall lower thalamic activations when compared to either of those two groups. Important is that having FBTCS in the last year was the most significant determinant of thalamic activation. The study would be very easy to understand and interpret had they stopped their analyses here. However, the authors performed several useful but very complicated analyses that undoubtedly make the interpretation of the results difficult. These additional, in-part confirmatory in-part follow-up analyses are psychophysiologic interaction, graph theory, and receiver operating characteristic (RUC) curve analyses. The understanding and interpretation of these analyses is neither intuitive nor simple. While disentangling these analyses is not part of this commentary, for the purpose of better understanding their approach, we can briefly state that psychophysiologic interaction is a between regions connectivity analysis for fMRI data that is context-dependent. Graph theory analysis, as explained previously in great detail, 5 allows mathematical analysis and description of complex systems using terms such as "hubs," "centrality," and "betweenness." Finally, the term ROC-probably most recognized by neurologists-is a binary classifier that allows diagnostic discrimination between groups. These analyses show that, in patients with active FBTCS, there is greater context-dependent thalamo-temporal and thalamomotor connectivity, higher thalamic degree and betweenness centrality, and that ROC curves discriminate well between individuals with and without active FBTCS. These findings also indicate that having active FBTCS changes the brain more than having FS alone and that the presence and the degree of the changes may be used as a biomarker for disease severity.

As complicated as these analyses are, the authors provide meticulous description of the procedures performed and of the results in the main body of the manuscript with additional details included in the supplement. However, more important are implications of this study. Since fMRI has been a mainstay of presurgical language and verbal memory evaluation for years, 6 most epilepsy centers obtain fMRI as part of their presurgical patient staging protocol. However, we cannot expect that psychophysiologic interaction, graph theory, and ROC curve analyses of the task-related fMRI data will be performed in the course of such evaluation. Rather, what the study shows is that the task fMRI data can be used not only to perform a rather simplistic analysis of language lateralization but also to identify the negative effects of pathophysiology (here seizures) on brain networks. Whether independently or in combination with other measures (eg, functional connectivity or thalamic stereoelectroencephalography), future research could teach us if/how such results could be applied to evaluating disease severity, staging in presurgical evaluation, predicting outcomes, or deciding the treatment approaches (eg, resection vs implantable devices).

Perhaps more importantly, these findings teach us something about the disease itself. They provide information about the pathophysiology of temporal lobe seizures, about the negative effects of seizures not only on local but also on remote executive brain regions (ie, confirm the proposed a long-time ago "nociferous cortex hypothesis" 7 ), and outline the negative effects of FBTCS on brain connectivity and pathways of information transfer. While previously such negative effects have been documented in resting-state studies, this effort extends those findings to cognitive tasks and task-based connectivity. This study shows that the task data can be used not only to localize and lateralize brain functions but also to measure the effects of the disease on brain networks and its severity. Given the evidence that SARS-CoV-2 can infect neurons and astrocytes, it is possible that the virus could cause seizures and epilepsy in nonepilepsy patients and worsened seizures in persons with epilepsy. Two studies conducted in early 2020 in New York City explored this. In one, the electroencephalograms (EEGs) of patients hospitalized with COVID-19 were examined. Epileptiform patterns were seen in 30% and seizures in 7% of 111 patients undergoing EEG monitoring. 4 In the second, 17.5% of adults with epilepsy reported worsened seizure control. 5 Emotional stress and barriers to care appeared to be substantial contributing factors. Additional research will almost certainly be conducted to determine whether SARS-CoV-2 infection is indeed epileptogenic.

Separate, but important, questions are whether people with epilepsy develop COVID-19, and whether they die from it more often, than people without epilepsy. Cabezudo-Garcia and colleagues 6 aimed to answer this. They studied patients with epilepsy age 14 years seen in the University of Malaga emergency department between March 13, 2020, and April 12, 2020. Video-EEG and magnetic resonance imaging were conducted as needed. Patients with nonepileptic seizures were excluded. The control group was all patients' age 14 years without epilepsy. They included patients with acute respiratory infections whose symptoms were consistent with COVID-19. As was common early in the pandemic when testing was not widely available, PCR tests were only done in moderate to severe disease, in mild disease with risk factors, and in all hospitalizations. The authors defined a confirmed case as one with a positive PCR test for SARS-CoV-2, a probable case as one with severe signs or who was hospitalized with clinical examination and X-ray findings consistent with COVID-19 (but not tested with PCR), and a possible case as one having mild symptoms (but not tested with PCR).

The authors defined the cumulative incidence as the number of epilepsy patients seen in the "COVID-19 patient flow" divided by the total number of epilepsy patients in the catchment area served by emergency department. That area contained 302 556 people, and the prevalence of epilepsy in Spain was 0.579%. Those data yielded an estimate of 1751 persons with epilepsy in the catchment area. In the month studied, 1537 patients were seen for possible, probable, and confirmed COVID-19, of whom 21 patients had epilepsy. Based upon the estimated prevalence of epilepsy in the community, the authors calculated that the incidence of COVID-19 in epilepsy patients was significantly higher (1.2%) than in the general population (0.5%). Considering only confirmed cases, the incidence of COVID-19 was higher in the 9 (0.5%) patients with epilepsy than in the 511 (0.1%) patients without epilepsy. The case fatality rate was higher in suspected COVID-19 patients with epilepsy than in controls, but when only confirmed (positive PCR) COVID-19 patients were included there was no significant difference in fatality rate between epilepsy and nonepilepsy patients. Of the 21 epilepsy patients, more than half were disabled and one-third were institutionalized.

This study has limitations that affect its generalizability. The first is that the prevalence of epilepsy varies based on study methodology and geographic location. Although the methodology of using a Spanish prevalence of 0.579% of epilepsy is logical, that number is lower than in other studies. For example, between 2013 and 2015 in the US National Health Interview Survey of the Centers for Disease Control, 1.1% of US adults reported having active epilepsy (a health care provider told them they had epilepsy or seizure disorder, they were taking anti-seizure medications for a seizure, or they had at least one seizure in the prior year). 7 By contrast, an international metaanalysis calculated a prevalence of 0.64% 8 and a recent Latin America systematic review and meta-analysis found an active prevalence of 0.9%. 9 Although rates may indeed differ among different populations, a major problem is the wide variation in the completeness of case ascertainment and the definitions of epilepsy used in studies on the epidemiology of epilepsy. If the Spanish prevalence is actually higher, then the cumulative incidence of epilepsy patients with COVID-19 is probably not statistically different from the control population.

A second limitation is that 1 of 3 of the epilepsy patients with COVID-19 in the University of Malaga emergency department in March to April 2020 came from institutions. That percentage is much higher than the living situation of most people with epilepsy. This time frame was at the early point in the pandemic when long-term care (LTC) facilities were being preferentially affected. At the time of this writing, the situation worldwide is very different with most COVID-19 cases and deaths coming from the general community. As a result, a similar study should be repeated to see whether overrepresentation of patients living in LTC facilities was a confounder.

A third limitation, which the authors acknowledge, is that PCR testing for SARS-CoV-2 was not widely available at the early stage of the pandemic during which the study was conducted. In their study, deaths from COVID-19 were not different between the 2 groups who had PCR-confirmed disease. 6 Testing is now widely available. Therefore, a new study including only test-proven COVID-19 patients should be conducted.

In conclusion, COVID-19 is not proven to be more common in epilepsy patients, and mortality from COVID-19 is not proven to be higher in epilepsy patients, than in controls based upon this study. Further research is warranted using persons with epilepsy residing in more representative living situations and using PCR confirmation in all patients.

David G. Vossler https://orcid.org/0000-0003-4823-0537

imaging biomarker for secondary generalization of seizures. However, the study methods and data/result presentation are complicated and require some attention before we dive deeper into the discussion of the results. The authors present data of a large but overall heterogeneous group of TLE patients-MRI-negative patients, patients with hippocampal sclerosis, dysembryoplastic neuroepithelial tumors, and cavernomas. While not necessarily a major problem, combining all these groups prior to showing that their task-related fMRI activations are not different (and that thalamic activations are not different) creates a potential confounder that is not addressed in the study. Further, they utilize their "goto" fMRI task-verb fluency-to assess language lateralization including thalamic involvement in the task. However, since there is no performance tracking with this covert task, there is no way of knowing how well the participants performed the task and how performance on the task influenced the observed fMRI activations. To offset this, they tested letter fluency as part of their neuropsychological battery-there were some group differences including significant differences between left TLE with and without generalized seizures.

In the primary analysis, they compared fMRI activation patterns in patients with FBTCS within the last year to patients with no FBTCS (ie, only with focal seizures [FS] ) in the last year to find that the activation patterns were different between the groups with higher fMRI activation and more leftward activation in patients with FS including differences in thalami. Of interest is the fact that some of the peak activations fell into the anterior thalamic nuclei that, as we all know, are the target of deep brain stimulation. In the post hoc analyses, they showed that FS patients' thalamic activations were similar to healthy controls performing the same task but active FBTCS participants had overall lower thalamic activations when compared to either of those two groups. Important is that having FBTCS in the last year was the most significant determinant of thalamic activation. The study would be very easy to understand and interpret had they stopped their analyses here. However, the authors performed several useful but very complicated analyses that undoubtedly make the interpretation of the results difficult. These additional, in-part confirmatory in-part follow-up analyses are psychophysiologic interaction, graph theory, and receiver operating characteristic (RUC) curve analyses. The understanding and interpretation of these analyses is neither intuitive nor simple. While disentangling these analyses is not part of this commentary, for the purpose of better understanding their approach, we can briefly state that psychophysiologic interaction is a between regions connectivity analysis for fMRI data that is context-dependent. Graph theory analysis, as explained previously in great detail, 5 allows mathematical analysis and description of complex systems using terms such as "hubs," "centrality," and "betweenness." Finally, the term ROC-probably most recognized by neurologists-is a binary classifier that allows diagnostic discrimination between groups. These analyses show that, in patients with active FBTCS, there is greater context-dependent thalamo-temporal and thalamomotor connectivity, higher thalamic degree and betweenness centrality, and that ROC curves discriminate well between individuals with and without active FBTCS. These findings also indicate that having active FBTCS changes the brain more than having FS alone and that the presence and the degree of the changes may be used as a biomarker for disease severity.

As complicated as these analyses are, the authors provide meticulous description of the procedures performed and of the results in the main body of the manuscript with additional details included in the supplement. However, more important are implications of this study. Since fMRI has been a mainstay of presurgical language and verbal memory evaluation for years, 6 most epilepsy centers obtain fMRI as part of their presurgical patient staging protocol. However, we cannot expect that psychophysiologic interaction, graph theory, and ROC curve analyses of the task-related fMRI data will be performed in the course of such evaluation. Rather, what the study shows is that the task fMRI data can be used not only to perform a rather simplistic analysis of language lateralization but also to identify the negative effects of pathophysiology (here seizures) on brain networks. Whether independently or in combination with other measures (eg, functional connectivity or thalamic stereoelectroencephalography), future research could teach us if/how such results could be applied to evaluating disease severity, staging in presurgical evaluation, predicting outcomes, or deciding the treatment approaches (eg, resection vs implantable devices).

Perhaps more importantly, these findings teach us something about the disease itself. They provide information about the pathophysiology of temporal lobe seizures, about the negative effects of seizures not only on local but also on remote executive brain regions (ie, confirm the proposed a long-time ago "nociferous cortex hypothesis" 7 ), and outline the negative effects of FBTCS on brain connectivity and pathways of information transfer. While previously such negative effects have been documented in resting-state studies, this effort extends those findings to cognitive tasks and task-based connectivity. This study shows that the task data can be used not only to localize and lateralize brain functions but also to measure the effects of the disease on brain networks and its severity.

Jerzy P. Szaflarski, MD, PhD

Jerzy P. Szaflarski, MD, PhD https://orcid.org/0000-0002-5936-6627

Thalamus and focal to bilateral seizures: a multiscale cognitive imaging study

Cortical and subcortical networks in human secondarily generalized tonic-clonic seizures

Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review

Thalamus and focal to bilateral seizures: a multiscale cognitive imaging study

Cortical and subcortical networks in human secondarily generalized tonic-clonic seizures

ApoE-isoform-dependent SARS-CoV-2 neurotropism and cellular response

Neurotropic effects of SARS-CoV-2 modeled by the human brain organoids

Continuous EEG findings in patients with COVID-19 infection admitted to a New York academic hospital system

Seizure control, stress, and access to care during the COVID-19 pandemic in New York City: the patient perspective

Incidence and case fatality rate of COVID-19 in patients with active epilepsy

Active epilepsy and seizure control in adults-United States

Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies

Prevalence and incidence of epilepsy in Latin America and the Caribbean: a systematic review and meta-analysis of population-based studies